![](/img/cover-not-exists.png)
A Phase II Study of Metronomic Daily Oral Vinorelbine as First-Line Chemotherapy in Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer Resistant to Endocrine Therapy: Vinometro
Thomssen, Christoph, Decker, Thomas, Fehm, Tanja, Fuxius, Stefan, Harbeck, Nadia, Juhasz-Böss, Ingolf, Möbus, Volker, Seehase, Martina, Schollenberger, Lukas, Ruckes, Christian, Schmidt, MarcusVolume:
36
Language:
english
Journal:
The Breast
DOI:
10.1016/s0960-9776(17)30701-4
Date:
November, 2017
File:
PDF, 42 KB
english, 2017